Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia

Blood

Volumn 107, Issue 9, 2006, Pages 3455-3462

  Cappellini, Maria Domenica ^a   Cohen, Alan ^b   Piga, Antonio ^b   Bejaoui, Mohamed ^b   Perrotta, Silverio ^b   Agaoglu, Leyla ^b   Aydinok, Yesim ^b   Kattamis, Antonis ^b   Kilinc, Yurdanur ^b   Porter, John ^b   Capra, Marcello ^b   Galanello, Renzo ^b   Fattoum, Slaheddine ^b   Drelichman, Guillermo ^b   Magnano, Carmelo ^b   Verissimo, Monica ^b   Athanassiou Metaxa, Miranda ^b   Giardina, Patricia ^b   Kourakli Symeonidis, Alexandra ^b   Janka Schaub, Gritta ^b   Coates, Thomas ^b   Vermylen, Christiane ^b   Olivieri, Nancy ^b   Thuret, Isabelle ^b   Opitz, Herbert ^b   Ressayre Djaffer, Catherine ^b   Marks, Peter ^b   Alberti, Daniele ^b   more..

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; BETA THALASSEMIA; CATARACT; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME DEFECT; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HUMAN; HUMAN TISSUE; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VOMITING; DRUG ADMINISTRATION; LIVER; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; SAFETY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MALE; MIDDLE AGED; SAFETY; TRIAZOLES;

EID: 33646414765     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3430     Document Type: Article

References (24)

1. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol. 2002;76:219-228.
2. Schrier SL, Angelucci E. New strategies in the treatment of thalassemias. Annu Rev Med. 2005;56:157-171.
3. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
4. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
5. Rund D, Rachmilewitz E. β-thalassemia. N Engl J Med. 2005;353:1135-1146.
6. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
7. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-252.
8. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
9. Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am. 1987;3:521-544.
10. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol. 2001;56:915-922.
11. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
12. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-1587.
13. Hoffbrand AV, Cohen A, Hershko C. The role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
14. Nick H-P, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065-1076.
15. Hershko C, Konijn AM, Nick H-P, et al. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-1122.
16. Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-3250.
17. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet; 2003;361:1597-1602.
18. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood. 1997;90:994-998.
19. Soriano-Cubells MJ, Aparisi-Querada L. Rapid determination of copper, iron and zinc in liver biopsies. Atomic Spectrosc. 1984;5:217-222.
20. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-331.
21. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic susceptibility measurement of human iron stores. N Eng J Med. 1982;307:1671-1675.
22. Fischer R, Tiemann CD, Engelhardt R, et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol. 1999;60:289-299.
23. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:1600-1603.
24. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73:359-366.